CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 630 enrolled
Drug / intervention
Managed Ventricular Pacing programmed ON/OFFdevice
Likely dose
Managed Ventricular Pacing (MVP) programmed ON/OFFAI-extracted
Key inclusion· 4
  • ✓Dual chamber device (including VDD) implanted for minimum 2 years
  • ✓Planned replacement or already replaced with device including MVP feature
  • ✓>40% ventricular pacing documented over ≥4 weeks before enrollment or device replacement
  • ✓No change needed to pacing mode or AV intervals
Key exclusion· 5
  • ✕Cardiac resynchronization therapy (CRT) indication
  • ✕Permanent atrial fibrillation
  • ✕Permanent AV block
  • ✕Unable to complete follow-up visits at study center

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00293241
NCT00293241Phase 4Completed
CompareCT.gov

PreFER MVP for Elective Replacement

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Feb 17, 2006·Updated Jun 24, 2016

In Brief

A Phase 4 clinical trial evaluating Managed Ventricular Pacing programmed ON/OFF for Cardiovascular Diseases. Completed, enrolled 630 participants across 1 site.

Detailed Summary

The purpose of this study is to demonstrate the benefit of MVP in pacemaker and implantable cardioverter defibrillator (ICD) patients with a history of right ventricular pacing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases
CountriesNetherlands
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 17, 2006
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 20.4 years ago

Interventions

Managed Ventricular Pacing programmed ON/OFFdevice

Device programming